Dr. Tolaney Discusses Neratinib in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Thursday, Aug 24, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Particularly, neratinib is showing progress in patients with HER2-positive hormone receptor-positive patients, as per results from the ExteNET trial.



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Although trastuzumab (Herceptin) remains the standard of care, the recent approval of neratinib could shake up treatment decisions for certain subgroups of breast cancer.

Particularly, neratinib is showing progress in patients with HER2-positive hormone receptor-positive patients, as per results from the ExteNET trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x